Ariola, Fidel .
HRN: 04-09-06 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/09/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/09/2025
10/15/2025
IV
350mg
Q8
DM Foot
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes